Company intelligence / Profile preview

Norbitec

Uetersen, Schleswig-Holstein, Germanynorbitec.de ↗

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

Norbitec is a leading European and US supplier of biotechnologically produced erythropoietin (Epoetin zeta), with more than 15 years of experience in biosimilar production. Its products are approved in Europe since 2007 and received FDA approval for the US market in 2023. The company is recognized for high-quality manufacturing standards and regulatory compliance, including recent FDA certification for its Uetersen facility.

Therapeutic areas: Hematology
Modalities: Recombinant proteinBiologic
Industry: Biotech

Drug pipeline

1 asset

epoetin zeta

Commercial

Indications: Anemia

Partnerships

Nordmark Pharma GmbH (joint venture partner)STADA Arzneimittel AG group companiesPfizer (manufacturing partnership for epoetin biosimilars)

Beyond the preview

Go deeper on Norbitec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Norbitec.

Explore the full profile